about
Functional assembly of Kv7.1/Kv7.5 channels with emerging properties on vascular muscle physiologyElisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell DeathIrvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cellsIn-Depth Study of the Interaction, Sensitivity, and Gating Modulation by PUFAs on K+ Channels; Interaction and New TargetsImmunomodulation of voltage-dependent K+ channels in macrophages: molecular and biophysical consequencesStereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5)Bupivacaine effects on hKv1.5 channels are dependent on extracellular pHEffects of propafenone and 5-hydroxy-propafenone on hKv1.5 channelsCell cycle-dependent expression of Kv1.5 is involved in myoblast proliferationBlockade of cardiac potassium and other channels by antihistamines.Gating of cardiac Na+ channels in excised membrane patches after modification by alpha-chymotrypsin.Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers.Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles.Pharmacology of cardiac potassium channels.Stereoselective interactions between local anesthetics and ion channels.Polyunsaturated Fatty acids modify the gating of kv channelsD242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence.Fludarabine Inhibits KV1.3 Currents in Human B Lymphocytes.Differential regulation of Na(v)beta subunits during myogenesis.Voltage-dependent Na+ channel phenotype changes in myoblasts. Consequences for cardiac repair.Kvbeta1.3 reduces the degree of stereoselective bupivacaine block of Kv1.5 channels.Effects of lisinopril on cardiac contractility and ionic currents.Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5).A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome.Functional expression of an inactivating potassium channel (Kv4.3) in a mammalian cell line.Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5.Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels.Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block.Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels.Protein kinase C (PKC) activity regulates functional effects of Kvβ1.3 subunit on KV1.5 channels: identification of a cardiac Kv1.5 channelosomeComparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels.Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials.Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels.Effects of a quaternary bupivacaine derivative on delayed rectifier K(+) currentsAssembly with the Kvbeta1.3 subunit modulates drug block of hKv1.5 channels.Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels.Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
P50
Q24298089-BB42B68B-0558-450C-B33E-CCDE78747BEDQ27312540-13B9D24E-19E8-4ACA-A124-496F29B185EBQ27346446-57492D36-9BED-4C89-9B5D-DCFD19DAE4A6Q28066803-69137467-66A2-4764-86D7-76F4A61C9C8BQ28271375-C33F10CB-88A9-4A3F-B20A-78AFA5743252Q28346372-40483278-C96C-4632-B2B9-D351AD395394Q28358879-1989C56A-205F-4E00-9D27-BB3ABE40A106Q28369361-4EEB3517-4CA8-48D3-847B-17AED8484816Q28573475-389A40CD-319D-447C-B7DE-19F3B10D4949Q33794463-7A8DC0E6-B68F-4BC9-8C34-E430A614E0A1Q34018174-4671CC28-9012-446E-8292-D590E34A1755Q34046966-98513DF5-4AD0-48C8-B3EC-F6472E093A9EQ35025380-36405975-A401-4D6C-A93D-8AA8B964C44BQ35692275-50C2EE1D-ED6A-4E25-89DE-6E8E54246809Q38016830-E9F868B3-197D-4F7C-9C29-A82F2307595FQ38042919-2D15C575-4AD1-4FCC-85C4-89D47D303995Q38663976-C751CE9F-CC4D-4CA6-95A3-2B97FA5A9929Q38837450-3705BA89-BB98-44AE-8758-EEE068901DE3Q40015008-3E093993-1E40-4E11-B4E3-225B94450A01Q40075283-5126490A-A4A8-481C-B751-6C675096E364Q40076623-5472958B-7D24-4FBB-A568-0BA8DD91B854Q40579566-E4AFD529-2934-4E3B-8E71-64C738069B42Q40703451-0BCEFB89-AAB6-40F1-BD11-9FED6DD3AC25Q40743734-980CAAB5-2076-49A8-9B13-F33A649696A7Q40954683-742D7CA2-C652-432B-BE7F-B6EBEB5A7108Q41066848-A15C9541-94EF-4DE5-A4BA-B05ADE000130Q41095531-60CEBD8F-4527-43C7-A733-26E4277D1A4DQ41767235-FE21872E-6499-4400-BBD8-CD9D0921059BQ42067930-792F16DD-D26E-4735-91FC-13B7B0CE1179Q42198666-C9D25196-71C6-452B-8BE5-2EB0953238DCQ42202086-A2374EEB-40A4-4F5A-89DE-21FAF785A5C3Q42549033-46361942-B65F-4EC0-BAE8-B08D4818C915Q42880713-BA81AE99-736F-4DF8-9CB0-79F4F138C888Q43058261-B4485278-2893-496F-994C-708494718AEFQ43105838-B27F0200-7164-4EB7-8AB6-78CADA3A0957Q43264506-E7F769A4-E1F6-43BE-A252-ED6E3CD5FAAAQ44219295-2E5A7720-D94A-4A69-AF58-2733D5306C1FQ44285594-9CDB3EDC-BF75-4DC5-9196-702F6F68FBAFQ44319424-4022583D-E119-4E74-81CE-1EADFA6DDFEEQ44346278-5265825A-36CE-452D-8C8B-226A0C638BCF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmen Valenzuela
@ast
Carmen Valenzuela
@en
Carmen Valenzuela
@es
Carmen Valenzuela
@nl
Carmen Valenzuela
@sl
type
label
Carmen Valenzuela
@ast
Carmen Valenzuela
@en
Carmen Valenzuela
@es
Carmen Valenzuela
@nl
Carmen Valenzuela
@sl
prefLabel
Carmen Valenzuela
@ast
Carmen Valenzuela
@en
Carmen Valenzuela
@es
Carmen Valenzuela
@nl
Carmen Valenzuela
@sl
P1053
L-3219-2015
P106
P1153
35820477800
P21
P2798
P31
P3829
P496
0000-0003-3929-1960